Broadwood Capital Inc Lineage Cell Therapeutics, Inc. Transaction History
Broadwood Capital Inc
- $1.53 Billion
- Q2 2025
A detailed history of Broadwood Capital Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Broadwood Capital Inc holds 49,560,992 shares of LCTX stock, worth $93.2 Million. This represents 2.94% of its overall portfolio holdings.
Number of Shares
49,560,992
Previous 49,560,992
-0.0%
Holding current value
$93.2 Million
Previous $22.3 Million
102.22%
% of portfolio
2.94%
Previous 1.86%
Shares
4 transactions
Others Institutions Holding LCTX
# of Institutions
136Shares Held
99.2MCall Options Held
368KPut Options Held
0-
Black Rock Inc. New York, NY9.56MShares$18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$15.9 Million0.0% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$10.1 Million6.02% of portfolio
-
Comerica Bank4.6MShares$8.65 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.6MShares$4.89 Million0.0% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $319M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...